Health and Healthcare

Amgen : AMGN

All Amgen Articles

720 Articles

Chris Lange | Jun 10, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | May 25, 2016 at 8:20 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | May 11, 2016 at 8:15 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these…

Paul Ausick | May 7, 2016 at 12:30 PM EDT

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the…

Chris Lange | May 1, 2016 at 10:50 AM EDT

Analysts Make Major Changes to Top Biotech Ratings

With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls…

Chris Lange | Apr 27, 2016 at 8:10 AM EDT

Short Sellers Run for Cover From Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Apr 12, 2016 at 9:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Mar 16, 2016 at 1:35 PM EDT

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol…

Chris Lange | Mar 10, 2016 at 8:05 AM EST

Short Sellers Back Off of Major Biotechs

The February 29 short interest data have been compared with the previous report, and short interest decreased across the board…

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 10, 2016 at 8:40 AM EST

Major Biotech Short Interest Continues to Be Mixed

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most…

Lee Jackson | Feb 1, 2016 at 9:50 AM EST

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the…

Chris Lange | Jan 28, 2016 at 4:31 PM EST

Amgen Posts Handy Beat on Estimates and Guidance

Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.

Chris Lange | Jan 28, 2016 at 8:35 AM EST

Short Sellers Increase Bets in Major Biotechs

Short interest increased in most of these selected biotech stocks for the most recent settlement date.

1 … 23 24 25 26 27 … 48

Amgen : AMGN

All Amgen Articles

Short Sellers Become More Selective on Major Biotechs

Short Sellers Grow More Selective on Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Analysts Adjust Predictions on Medivation Buyout Price

Analysts Make Major Changes to Top Biotech Ratings

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Amgen Posts Handy Beat on Estimates and Guidance

Short Sellers Increase Bets in Major Biotechs

How a 56-Year-Old Turned a $735,000 401(k) Rollover Into a $4,300 Monthly Paycheck Without Buying an Annuity

New for 2026: Workers 60 to 63 Can Put Away an Extra $11,250. Almost Nobody Does.

Want $10,000 a Year on $100K? The Private-Credit Funds Banks Can’t Compete With Pay 10%+

How a 56-Year-Old Turned a $735,000 401(k) Rollover Into a $4,300 Monthly Paycheck Without Buying an Annuity

New for 2026: Workers 60 to 63 Can Put Away an Extra $11,250. Almost Nobody Does.

How a 56-Year-Old Turned a $735,000 401(k) Rollover Into a $4,300 Monthly Paycheck Without Buying an Annuity

New for 2026: Workers 60 to 63 Can Put Away an Extra $11,250. Almost Nobody Does.

Amgen : AMGN

All Amgen Articles

Short Sellers Become More Selective on Major Biotechs

Short Sellers Grow More Selective on Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Analysts Adjust Predictions on Medivation Buyout Price

Analysts Make Major Changes to Top Biotech Ratings

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Short Sellers Back Off of Major Biotechs

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Amgen Posts Handy Beat on Estimates and Guidance

Short Sellers Increase Bets in Major Biotechs

How a 56-Year-Old Turned a $735,000 401(k) Rollover Into a $4,300 Monthly Paycheck Without Buying an Annuity

New for 2026: Workers 60 to 63 Can Put Away an Extra $11,250. Almost Nobody Does.

Want $10,000 a Year on $100K? The Private-Credit Funds Banks Can’t Compete With Pay 10%+

Featured Reads

How a 56-Year-Old Turned a $735,000 401(k) Rollover Into a $4,300 Monthly Paycheck Without Buying an Annuity

New for 2026: Workers 60 to 63 Can Put Away an Extra $11,250. Almost Nobody Does.